Qiagen Posts Robust Q2 Non-COVID Sales Growth, Lifts Annual Guidance

  • Qiagen N.V. QGEN clocked Q2 FY22 revenues of $516 million, down 9% Y/Y, well above the consensus of $488.73 million.
  • At constant exchange rates (CER), Qiagen's Q2 sales fell 4 percent to $544 million, besting previous company guidance of $510 million at CER. 
  • Qiagen's non-COVID product groups, now comprising more than 80% of its sales, rose 4% (10% at CER) to $423 million, tempered by an expected decline of 42% (39% at CER) in its COVID-19 products to $92 million.
  • Adjusted EPS reached $0.51 ($0.53 CER), down from $0.67 a year ago and ahead of the outlook for at least $0.46 CER.
  • Guidance: Qiagen raised FY22 sales guidance to at least $2.2 billion CER (prior outlook for at least $2.12 billion).
  • It also expects adjusted EPS of at least $2.30 at CER for full-year 2022, up from previous guidance of $2.14 at CER.
  • The updated guidance includes a goal for double-digit CER sales growth from the non-COVID product groups, which grew 12% CER in 1H of 2022, but for a decline in COVID-19 sales amid volatile pandemic trends. 
  • It also reflects a review of macro-economic trends, including inflation and energy supplies.
  • Price Action: QGEN shares closed at $47.88 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!